Iterum Therapeutics Plc Stock Price on December 12, 2024
| ITRM Stock | USD 1.98 0.32 13.91% |
Below is the normalized historical share price chart for Iterum Therapeutics PLC extending back to May 25, 2018. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Iterum Therapeutics stands at 1.98, as last reported on the 13th of December 2024, with the highest price reaching 2.27 and the lowest price hitting 1.85 during the day.
If you're considering investing in Iterum Stock, it is important to understand the factors that can impact its price. Iterum Therapeutics is abnormally volatile given 3 months investment horizon. Iterum Therapeutics PLC holds Efficiency (Sharpe) Ratio of 0.14, which attests that the entity had a 0.14% return per unit of risk over the last 3 months. We were able to interpolate data for twenty-nine different technical indicators, which can help you to evaluate if expected returns of 1.48% are justified by taking the suggested risk. Use Iterum Therapeutics PLC Market Risk Adjusted Performance of 0.7232, downside deviation of 8.11, and Risk Adjusted Performance of 0.1202 to evaluate company specific risk that cannot be diversified away.
At this time, Iterum Therapeutics' Common Stock Total Equity is very stable compared to the past year. As of the 13th of December 2024, Sale Purchase Of Stock is likely to grow to about 31.7 M, while Common Stock Shares Outstanding is likely to drop about 12.3 M. . At this time, Iterum Therapeutics' Price To Sales Ratio is very stable compared to the past year. As of the 13th of December 2024, Price Earnings To Growth Ratio is likely to grow to 0.04, while Price Book Value Ratio is likely to drop (4.19). Iterum Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 25th of May 2018 | 200 Day MA 1.3837 | 50 Day MA 1.5119 | Beta 2.248 |
Iterum |
Sharpe Ratio = 0.1402
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ITRM | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 10.56 actual daily | 94 94% of assets are less volatile |
Expected Return
| 1.48 actual daily | 29 71% of assets have higher returns |
Risk-Adjusted Return
| 0.14 actual daily | 11 89% of assets perform better |
Based on monthly moving average Iterum Therapeutics is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Iterum Therapeutics by adding it to a well-diversified portfolio.
Price Book 6.0287 | Enterprise Value Ebitda 0.5453 | Price Sales 1.3 K | Shares Float 22 M | Wall Street Target Price 7.5 |
Related Headline
Fortress Biotech Headline on 12th of December 2024
Fortress Investment Group CEOs ride crest of Yall Street wav... by bizjournals.com
Josh Pack, left, and Drew McKnight are co-CEOs of Fortress Investment Group.
Iterum Therapeutics Valuation on December 12, 2024
It is possible to determine the worth of Iterum Therapeutics on a given historical date. On December 12, 2024 Iterum was worth 2.12 at the beginning of the trading date compared to the closed value of 1.98. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Iterum Therapeutics stock. Still, in general, we apply an absolute valuation method to find Iterum Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Iterum Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Iterum Therapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 2.12 | 2.27 | 1.85 | 1.98 | 2,912,582 | |
12/13/2024 | 2.12 | 2.27 | 1.85 | 1.98 | 0.00 |
| Backtest Iterum Therapeutics | | | Iterum Therapeutics History | | | Iterum Therapeutics Valuation | Previous |
Iterum Therapeutics Trading Date Momentum on December 12, 2024
| On December 13 2024 Iterum Therapeutics PLC was traded for 1.98 at the closing time. The top price for the day was 2.27 and the lowest listed price was 1.85 . There was no trading activity during the period 0.0. Lack of trading volume on December 13, 2024 did not cause price change. The trading delta at closing time against the current closing price is 7.07% . |
Iterum Therapeutics PLC Fundamentals Correlations and Trends
By evaluating Iterum Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Iterum Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Iterum financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Iterum Therapeutics Stock history
Iterum Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Iterum is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Iterum Therapeutics PLC will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Iterum Therapeutics stock prices may prove useful in developing a viable investing in Iterum Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 13 M | 12.3 M | |
| Net Loss | -40 M | -42 M |
Iterum Therapeutics Stock Technical Analysis
Iterum Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Iterum Therapeutics Period Price Range
Low | December 13, 2024
| High |
0.00 | 0.00 |
Iterum Therapeutics PLC cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Iterum Therapeutics December 13, 2024 Market Strength
Market strength indicators help investors to evaluate how Iterum Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Iterum Therapeutics shares will generate the highest return on investment. By undertsting and applying Iterum Therapeutics stock market strength indicators, traders can identify Iterum Therapeutics PLC entry and exit signals to maximize returns
Iterum Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Iterum Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Iterum Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Iterum to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.1202 | |||
| Jensen Alpha | 1.36 | |||
| Total Risk Alpha | 0.1212 | |||
| Sortino Ratio | 0.1823 | |||
| Treynor Ratio | 0.7132 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iterum Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iterum Therapeutics. If investors know Iterum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iterum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.76) | Quarterly Revenue Growth (1.00) | Return On Assets (0.73) | Return On Equity (5.56) |
The market value of Iterum Therapeutics PLC is measured differently than its book value, which is the value of Iterum that is recorded on the company's balance sheet. Investors also form their own opinion of Iterum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iterum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iterum Therapeutics' market value can be influenced by many factors that don't directly affect Iterum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iterum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iterum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iterum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.